Breast Fibroadenoma Management: Treatment Without Surgery
Statistics reveal that fibroadenomas are one of the most prevalent breast conditions, affecting approximately 10% of women at some point in their lives. Yet, available treatment options for these non-cancerous breast tumors have traditionally been limited and often involve invasive surgery, leading to a need for more effective and less invasive treatment options. In this […]
Cryoablation for Breast Cancer – Evidence to date
Cryoablation, the use of extreme cold to destroy tumors by freezing, is emerging as an innovative treatment for breast cancer*, a disease that impacts approximately one in eight women in their lifetime. Current standards of breast cancer treatment can involve surgery, radiation, chemotherapy, hormone therapy, and targeted therapy. As a minimally invasive treatment compared to […]
Liquid Nitrogen Cryoablation – Advancing the Frontiers of Tumor Cryoablation
The medical world is increasingly embracing cryotherapy for tumor treatment, but not all cryoablation treatments are created equal. Liquid nitrogen (LN2) cryoablation technology, the coldest of the cryogens, is taking the stage for more effective treatment and outcomes. Cryoablation has become an established method of therapy in the corridors of oncology, enabling minimally invasive treatment […]
Breast Cancer Awareness Month: How Care Has Transformed In 2020
During Breast Cancer Awareness Month, IceCure’s VP of Business Development and Global Marketing, Tlalit Bussi Tel Tzure, was featured in a Forbes Business Development Council Article entitled “Breast Cancer Awareness Month: How Care Has Transformed in 2020.” The article shares Tlalit’s firsthand insights on how the health system, faced with unprecedented challenges during the COVID-19 pandemic, has […]
Join IceCure’s Live Specialty Webinar on Bone Tumor Cryoablation, Nov. 17th 2020
FOR INTERVENTIONAL ONCOLOGISTS AND ONCOLOGISTS Register here to join this unique webinar on bone tumor cryoablation on Tuesday November 17th at 13:00 CET, in collaboration with the European Institute of Oncology (EIO) in Milan, Italy. We are honored to host Director of the Division of Interventional Radiology at EIO, Franco Orsi, MD, PhD, EBIR, together with Deputy […]
IceCure shares first published results using the Prosense cryoablation system in kidney cancer
“None of the treated tumor lesions demonstrated contrast enhancement or growth on follow up imaging indicating a 100% oncologic success.” The full research was published in the Journal of Molecular and Clinical Medicine and conducted by Bnai Zion Medical Center in Israel by Dr. Sagi Shprits, Dr. Robert Sachner, Prof Ofer Nativ and Dr Sarel […]
COVID-19 Pandemic: Now is the Time to Embrace Healthcare Innovation by Tlalit Bussi
In this article, IceCure’s VP Business Development and Marketing, Tlalit Bussi Tel-Tzure’s discusses healthcare innovation in the time of COVID-19. The healthcare landscape has forever changed – are you ready? Read the full article here!
ICECURE’S PROSENSE® TUMOR FREEZING PRODUCT APPROVED FOR MARKET IN SOUTH AFRICA
Following IceCure’s accelerating global expansion, the company has received regulatory approval for the treatment of benign and cancerous tumors in many indications including for the breast, lung, bone and kidney. Through their new exclusive partner,Tecmed Africa, IceCure’s technology will lead the field in bringing cryoablation to South Africa. Read more
IceCure’s Global Expansion Accelerates; Tumor Freezing Product Now Approved for Market in India
New Indian regulatory approval received for its cryoablation technology to destroy tumors in extensive indications, including for breast, lung, bone and kidney cancer. Read more.
IceCure Enters German Cryoablation Oncology Market; Inks Exclusive Distribution Agreement with MTS Medical Technology
New German Territory Follows Accelerating Global Expansion with Orders in Singapore and Thailand This Month for Its Freezing Technology to Destroy Tumors. Read more.
